APA (7th ed.) Citation

Lianne, K., Sander, E., Xiangjun, K., Ma, J., Michelle, M., Hall, E., . . . Gavin, B. (2025). 346 Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A11: 01 that is multi-armored to increase epitope sensitivity. Journal for immunotherapy of cancer, 13(Suppl 2), A396. https://doi.org/10.1136/jitc-2025-SITC2025.0346

Chicago Style (17th ed.) Citation

Lianne, Kok, et al. "346 Pre-clinical Characterization of AZD0240, a CRISPR-engineered Autologous TCR-T Cell Product Targeting KRAS-G12D/HLA-A11: 01 That Is Multi-armored to Increase Epitope Sensitivity." Journal for Immunotherapy of Cancer 13, no. Suppl 2 (2025): A396. https://doi.org/10.1136/jitc-2025-SITC2025.0346.

MLA (9th ed.) Citation

Lianne, Kok, et al. "346 Pre-clinical Characterization of AZD0240, a CRISPR-engineered Autologous TCR-T Cell Product Targeting KRAS-G12D/HLA-A11: 01 That Is Multi-armored to Increase Epitope Sensitivity." Journal for Immunotherapy of Cancer, vol. 13, no. Suppl 2, 2025, p. A396, https://doi.org/10.1136/jitc-2025-SITC2025.0346.